Large, real-world, prospective study shows Inivata’s liquid biopsy test is able to provide molecular profile when tissue is unavailable and guide personalized treatment
High levels of concordance, sensitivity and specificity validate InVision in advanced NSCLC
This new product will help pharmaceutical companies to assess drug safety risks, inform go/no-go decisions in lead selection, and expedite drug discovery programs
Wickham Laboratories is proud to present a live webinar on 'Microbiological Considerations in Cleanroom Validation' conducted by our Microbiology Business Support Co-ordinator and one of our QC Laboratory Senior Technicians.
Any contamination, microbiological or otherwise, is a major safety concern during the development of pharmaceuticals and medical devices.
Life science start-ups are invited to apply for the opportunity to win access to the Babraham Research Campus bio-incubator facilities, plus an extended programme of support and mentoring
Inivata Receives Medicare Final Coverage Decision for InVisionFirst-Lung Liquid Biopsy Test in
Advanced Non-Small Cell Lung Cancer
Final Coverage Supports the Use of InVisionFirst-Lung for Aiding in the Management of Patients with Advanced NSCLC
Research Triangle Park, NC and Cambridge, UK, March 5, 2019 -- Inivata, a leader in liquid biopsy, today announces that Palmetto GBA, a Medicare Administrative Contractor recognized for its molecular diagnostic technology assessment experience through its assessment group, MolDx, has issued its final Coverage Determination for InVisionFirst™-Lung Liquid Biopsy test, a blood-based circulating tumor DNA (ctDNA) test for the detection of genomic alterations in the most commonly mutated genes in advanced Non-Small Cell Lung Cancer (N
Cambridge, UK, 26 February: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today confirmed its latest patent grant in the US. The US patent is part of PredictImmune’s third family of intellectual property (IP) relating to methods for predicting autoimmune disease risk. This follows successful grants across the company’s first family of IP in the UK and Europe in October 2018 and Canada in January this year.
Cambridge UK: 25 February 2019 - Lonza Biologics becomes the latest One Nucleus Partner. The Partner Program is tailor-made to meet the needs both of the Partner and the interests of One Nucleus members.
18 February 2019 – Oxford: Oxford Genetics and Sphere Fluidics announce a multi-partner collaboration to expedite the development of automated microfluidic systems for rapid and high-throughput gene editing in mammalian cell lines.